載入...
Multi-Trial Evaluation of Progression-Free Survival (PFS) as a Surrogate Endpoint for Overall Survival (OS) in First-Line Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
INTRODUCTION: We previously reported that PFS may be a candidate surrogate endpoint for OS in first-line ES-SCLC using data from 3 randomized trials (Foster, Cancer 2011). In this validation study (N0424-Alliance), we assessed the patient- and trial-level surrogacy of PFS using data from 7 new first...
Na minha lista:
| 發表在: | J Thorac Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4493926/ https://ncbi.nlm.nih.gov/pubmed/26134227 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0000000000000548 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|